Increasing evidence suggested that CXCR4 could be regarded as a putative CSCs marker in various malignancies, including glioma, non-small cell lung cancer, prostate cancer, renal cell carcinoma, and breast cancer (15, 16). This evidence concerns the gene CXCR4 and breast carcinoma.